Novelion Therapeutics (NVLNF) Stock Price, News & Analysis

Company Overview

Novelion Therapeutics is a specialty biopharmaceutical company focused on developing and delivering therapies for patients with rare and ultra-rare diseases. The firm pursues innovative treatments in areas such as lysosomal storage disorders and other metabolic genetic conditions. Novelion’s strategy combines in-house research and strategic partnerships to advance its pipeline through clinical development and regulatory approval.

The company’s product portfolio includes enzyme replacement therapies, substrate reduction approaches and next-generation modalities aimed at addressing the underlying causes of inherited metabolic disorders. Novelion leverages proprietary formulation technologies to improve drug delivery and patient convenience, while collaborating with academic centers and contract research organizations to accelerate trial progress. In addition to internal programs, the company has secured licensing agreements with global pharmaceutical partners to expand its reach and resource base.

With operations spanning North America, Europe and select Asian markets, Novelion maintains a network of commercial affiliates and distribution channels to ensure timely access for patients and healthcare providers. The organization’s regional teams work closely with regulatory agencies and patient advocacy groups to support disease awareness, diagnostic initiatives and clinician education programs.

Headquartered in Dublin, Ireland, Novelion Therapeutics is led by an experienced management team with deep expertise in rare disease drug development, regulatory affairs and global commercialization. Under the direction of CEO Michael Biondo and Chief Scientific Officer Dr. Lena Park, the company continues to reinforce its commitment to improving long-term outcomes for underserved patient populations worldwide.

Key Stats

• Today's Range: $0.70 to $0.75
• 50-Day Range: $0.70 to $0.70
• 52-Week Range: $0.51 to $1.00
• Volume: 26,900 shs
• Average Volume: 261,364 shs
• Market Capitalization: $13.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NVLNF Stock Analysis - Frequently Asked Questions

How have NVLNF shares performed this year?

Novelion Therapeutics' stock was trading at $0.7020 at the beginning of the year. Since then, NVLNF shares have increased by 0.0% and is now trading at $0.7020.

How do I buy shares of Novelion Therapeutics?

Shares of NVLNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:NVLNF
• CIK: N/A
• Web: www.novelion.com
• Phone: 617-500-7867
• Fax: N/A
• Employees: 109
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $130.43 million
• Price / Sales: 0.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.69) per share
• Price / Book: -0.15

Miscellaneous

• Outstanding Shares: 19,619,000
• Free Float: N/A
• Market Cap: $13.77 million
• Optionable: Not Optionable
• Beta: 2.15